TYRA vs. TWST, XENE, ACAD, VCEL, ZLAB, MLTX, MOR, BHC, MRUS, and RXRX
Should you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include Twist Bioscience (TWST), Xenon Pharmaceuticals (XENE), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Zai Lab (ZLAB), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Bausch Health Companies (BHC), Merus (MRUS), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry.
Tyra Biosciences vs.
Twist Bioscience (NASDAQ:TWST) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership.
Tyra Biosciences has a net margin of 0.00% compared to Twist Bioscience's net margin of -66.69%. Tyra Biosciences' return on equity of -24.56% beat Twist Bioscience's return on equity.
In the previous week, Tyra Biosciences had 5 more articles in the media than Twist Bioscience. MarketBeat recorded 11 mentions for Tyra Biosciences and 6 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.74 beat Tyra Biosciences' score of 0.51 indicating that Twist Bioscience is being referred to more favorably in the media.
Tyra Biosciences has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.
84.1% of Tyra Biosciences shares are owned by institutional investors. 3.0% of Twist Bioscience shares are owned by insiders. Comparatively, 15.4% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Twist Bioscience has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Twist Bioscience presently has a consensus target price of $51.90, suggesting a potential downside of 0.90%. Tyra Biosciences has a consensus target price of $30.50, suggesting a potential upside of 110.93%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Twist Bioscience.
Twist Bioscience received 68 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 75.00% of users gave Tyra Biosciences an outperform vote while only 59.06% of users gave Twist Bioscience an outperform vote.
Summary
Tyra Biosciences beats Twist Bioscience on 12 of the 17 factors compared between the two stocks.
Get Tyra Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tyra Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:TYRA) was last updated on 2/1/2025 by MarketBeat.com Staff
